FUSION PROTEINS: APPLICATIONS AND CHALLENGES - Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges - page 18

of the protein fractions of human plasma. J. Clin. Invest. 23,
417-432.
2. Krauss J, Arndt MAE, Vu BK, Newton DL, Rybak SM.
(2005) Targeting malignant B-cell lymphoma with a human-
ized anti-CD22 scFv-angiogenin immunoenzyme. Br. J.
Haematol. 128(5), 602-609.
3. Goeddel DV, Kleid DG, Bolivar F, Heyneker HL, Yansura
DG, Crea R, et al. (1979) Expression in Escherichia coli of
chemically synthesized genes for human insulin. Proc. Natl.
Acad. Sci. USA 76(1), 106-110.
4. Kohler G, Milstein C. (1975) Continuous cultures of fused
cells secreting antibody of predefined specificity. Nature 256
(5517), 495-497.
5. Kempeni J. (1999) Preliminary results of early clinical trials
with the fully human anti-TNFalpha monoclonal antibody
D2E7. Ann. Rheum. Dis. 58(Suppl. 1), I70-72.
6. Peppel K, Crawford D, Beutler B. (1991) A tumor necrosis
factor (TNF) receptor-IgG heavy chain chimeric protein as a
bivalent antagonist of TNF activity. J. Exp. Med. 174(6),
1483-1489.
7. Cai Q, Peng G, Bu L, Lin Y, Zhang L, Lustigmen S, et al.
(2007) Immunogenicity and in vitro protective efficacy of a
polyepitope plasmodium falciparum candidate vaccine con-
structed by epitope shuffling. Vaccine 25(28), 5155-5165.
8. Teicher BA, Chari RVJ. (2011) Antibody conjugate thera-
peutics: challenges and potential. Clin. Cancer Res. 17(20),
6389-6397.
9. Edwards PAW. (2010) Fusion genes and chromosome trans-
locations in the common epithelial cancers. J. Pathol. 220(2),
244-254.
10. Terpe K. (2003) Overview of tag protein fusions: from
molecular and biochemical fundamentals to commercial
systems. Appl. Microbiol. Biotechnol. 60(5), 523-533.
11. Schmidt SR. (2009) Fusion-proteins as biopharmaceuticals:
applications and challenges. Curr. Opin. Drug Discov. Dev.
12(2), 284-295.
12. Leader B, Baca QJ, Golan DE. (2008) Protein therapeutics: a
summary and pharmacological classification. Nat. Rev. Drug
Discov. 7(1), 21-39.
13. Gebauer M, Skerra A. (2009) Engineered protein scaffolds as
next-generation antibody therapeutics. Curr. Opin. Chem.
Biol. 13(3), 245-255.
14. Schmidt S.R. (2008) Fusion-Proteins as Biopharmaceuti-
cals: Applications and Challenges. Protein Expression
Europe & Antibodies Europe. Lisbon, Portugal, 20-23
October.
15. Schellekens H. (2004) When biotech proteins go off-patent.
Trends Biotechnol. 22(8), 406-410.
16. Webber PM. (2007) The patenting of novel biotech products.
IDrugs 10(7), 459-462.
17. Ilag LL, Ilag LM, Ilag LL. (2002) From patenting genes to
proteins: the search for utility via function. Trends Biotech-
nol. 20(5), 197-199.
18. Webber P. (2006) Patenting antibodies. Nat. Rev. Drug Dis-
cov. 5(2), 97.

19. Hashimoto K, Aida T. (2008) Antibody patenting without
antibodies: a global trend. Nat. Biotechnol. 26(12), 1341-1343.
20. Holliday L. (2009) Patenting antibodies in Europe. MAbs 1
(4), 385-386.
21. Bachran C, SutherlandM, Bachran D, Fuchs H. (2007) Patents
on immunotoxins and chimeric toxins for the treatment of
cancer. Recent Pat. Drug Deliv. Formul. 1(2), 105-115.
22. McCabe KW. (2009) Guardians at the gate: patent protection for
therapeutic monoclonal antibodies (Part 1). MAbs 1, 382-384.
23. Agris CH. (1998) Patenting protein sequences. Nat. Biotech.
16(11), 1075.
24. Dorey E. (2010) Bristol-Myers Squibb reaps biologics in
ZymoGenetics windfall. Nat. Biotech. 28, 1137-1138.
25. Marshall SA, Lazar GA, Chirino AJ, Desjarlais JR. (2003)
Rational design and engineering of therapeutic proteins. Drug
Discov. Today 8(5), 212-221.
26. Cuesta AM, Sainz-Pastor N, Bonet J, Oliva B, Alvarez-
Vallina L. (2010) Multivalent antibodies: when design sur-
passes evolution. Trends Biotechnol. 28(7), 355-362.
27. Ortiz-Sanchez E, Helguera G, Daniels TR, Penichet ML.
(2008) Antibody-cytokine fusion proteins: applications in
cancer therapy. Expert Opin. Biol. Ther. 8, 609-632.
28. Oliner J, Min H, Leal J, Yu D, Rao S, You E, et al. (2004)
Suppression of angiogenesis and tumor growth by selective
inhibition of angiopoietin-2. Cancer Cells 6(5), 507-516.
29. Evans L, Hughes M, Waters J, Cameron J, Dodsworth N,
Tooth D, et al. (2010) The production, characterisation and
enhanced pharmacokinetics of scFv-albumin fusions
expressed in Saccharomyces cerevisiae. Protein Expr. Purif.
73(2), 113-124.
30. Zhao HL, Xue C, Wang Y, Li XY, Xiong XH, Yao XQ, et al.
(2007) Circumventing the heterogeneity and instability of
human serum albumin-interferon-alpha2b fusion protein by
altering its orientation. J. Biotechnol. 131(3), 245-252.
31. Paek S-Y, Kim Y-S, Choi S-G. (2010) The orientation-
dependent expression of angiostatin-endostatin hybrid pro-
teins and their characterization for the synergistic effects of
antiangiogenesis. J. Microbiol. Biotechnol. 20(10), 1430-
1435.
32. Christensen T, Amiram M, Dagher S, Trabbic-Carlson K,
Shamji MF, Setton LA, et al. (2009) Fusion order controls
expression level and activity of elastin-like polypeptide
fusion proteins. Protein Sci. 18(7), 1377-1387.
33. Arndt MAE, Krauss J, Vu BK, Newton DL, Rybak SM.
(2005) A dimeric angiogenin immunofusion protein mediates
selective toxicity toward CD22 þ tumor cells. J. Immunother.
28(3), 245-251.
34. Mariuzza RA, Poljak RJ, Mihaesco C, Mihaesco E. (1983)
Crystals of the human heavy chain disease protein Riv and
human Fc fragment are isomorphous: further evidence for
conformational flexibility in the hinge region of immunoglo-
bulins. J. Mol. Biol. 165(3), 559-561.
35. Wriggers W, Chakravarty S, Jennings PA. (2005) Control of
protein functional dynamics by peptide linkers. Biopolymers
80(6), 736-746.